The effect of dried leaves of Stevia in the treatment of diabetes, non-alcoholic fatty liver and obesity

the Effect of Stevia Dry Leaves on Serum Levels of Liver Enzymes, Lipid Profile, Glycemic Indicators, Adiponectin and Leptin in Overweight and Obese Diabetic Patients with Non-Alcoholic Fatty Liver

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181119041701N1

Enrollment

Registered

2019-07-05

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes. Condition 2: Non-alcoholic fatty liver. Type 2 diabetes mellitus without complications Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Everyone will receive 2 capsules 250 mg stevia per day for 8 weeks. Intervention 2: Control group: Everyone will receive placebo, starch, 2 capsules 250 mg per day

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diabetic patients Overweight and obese Non-alcoholic fatty liver Having an ultrasound sheet with a diagnosis of non-alcoholic fatty liver In the age range of 20 to 60 years

Exclusion criteria

Exclusion criteria: Pregnancy and lactation liver transplantation smoking, alcohol and drugs complete intake of venous heart failure kidney diseases hereditary hematocromatosis and Wilson Having a positive test for hepatitis C, B and autoimmune hepatitis

Design outcomes

Primary

Measure	Time frame
Lipid profile. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Liver Enzymes. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Fasting blood sugar. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Insulin resistance. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Using the HOMA-IR formula.;Leptin. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Adiponectin. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Body mass index. Timepoint: Before and after 8 weeks of intervention. Method of measurement: The weight ratio in kilograms to the second power of height in meters.	—

Measure

Time frame

Lipid profile. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Liver Enzymes. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Fasting blood sugar. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Insulin resistance. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Using the HOMA-IR formula.;Leptin. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Adiponectin. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Laboratory test.;Body mass index. Timepoint: Before and after 8 weeks of intervention. Method of measurement: The weight ratio in kilograms to the second power of height in meters.

—

Secondary

Measure	Time frame
Systolic blood pressure. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Mercury pressure gauge.;Diastolic blood pressure. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Mercury pressure gauge.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReyhaneh Mazrae

Ahvaz University of Medical Sciences

Mazrae.r@gmail.com+98 61 3373 8383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026